Cetyl Myristoleate is an oil existing within the classifications of a free and unsaturated fatty acid (myristoleic acid). Myristoleic acids are abundant in the oils of fish, dairy butter(s), whale, and kombo butter. This acid existed in biological obscurity until the scientific exploration of one man, Dr. Harry W. Diehl (a specialist in sugar chemistry employed at the National Institute of Arthritis, Metabolism, and Digestive diseases), with added reference to his accompanying patents of Cetyl Myristoleate in 1977. 
Diehl’s passion for discovering a cure for arthritis began over 40 years ago and the discovery of CMO may be heralded as one of the greatest nutrition-based discoveries of the past century. His research began with mammalian studies, with the focus of trying to induce arthritis in a controlled mice and rat populous. He soon discovered through different scientific applications and peer evaluation, mice are simply not capable of developing arthritis. [2, 3]
The clinical studies by Diehl and associates indicated that Cetyl Myristoleate gave protection from adjuvant-induced arthritis in rats. Diehl would set out to prove this theory in human physiology, with an direct emphasis on the nutritional supplementation of CMO and its resounding effects of persons suffering from rheumatoid arthritis.
The majority of nutritional supplements containing Cetyl Myristoleate are synthetic. The only areas in nature where this nutrient is certain to exist are in sperm whale oils, male beavers (spec. glands), palm kernel oil, kombo extract, and the bone marrow of cow. Supplementation is available via creams, topical lotions, and in highly refined capsules and tablets.
Many dietary factors contribute to the benefits and overall absorption of CMO. As with all oils, Cetyl Myristoleate requires lipase for adequate consumption and usage within the body. (Lipase is an enzyme required for the digestion of fats/fat soluble vitamins) This point is critical, as enzymatic declination in human physiology is paralleled to age and health status.
Caffeine and alcohol consumption should remain minimal when supplementing with CMO. Certain sugary beverages (i.e. colas & citrus juices) may even inhibit the digestion and absorption of Cetyl Myristoleate altogether. Individuals suffering from various chronic inflammatory and joint diseases should use dietary discretion when supplementing with this nutrient.
Arthritis is a disease that effects, either directly or indirectly, greater than fifty million Americans. This condition remains a threat and serious burden to the health care industry. It is estimated that the more than 27 types of arthritis account for this condition - the number one cause and influence towards adult limitation of movement and disabilities.  Supplemental Cetyl Myristoleate may directly benefit certain types of non-infective arthritis.
There have been documented improvements in clinical applications of both osteoarthritis and rheumatoid arthritis sufferers. [5, 6] Evidence of these studies have concluded that supplemental Cetyl Myristoleate may assist in decreasing the stiffness and pain associated with severe arthritis, while helping to increase range of motion. These studies have proved beneficial for the future legitimacy of applications for this nutrient, as there is an approximate projection of nearly 100 underlying causes for varying forms of adult arthritis. 
A popular double-blind study vigorously sought to prove the benefits of CMO supplementation in nearly 340 individuals. All persons in the conducted clinical testing had previously attempted taking prescription non-steroidal anti-inflammatory drugs (NSAIDs) with either minor, or no success in diminishing the adverse symptoms brought on by arthritis. 106 participants received Cetyl Myristoleate, while the remaining 226 people were given placebo. An astounding 63.5% of patients receiving Cetyl Myristoleate showed a marked improvement in comparison to the diminutive percentage of those receiving placebo, some 14.5%. 
Synergistic combinations of CMO with other nutrients, such as omega-3 fish oils, flaxseed oils, Vitamin E, and glucosamine sulfate, have yielded even greater results in the suppression of arthritic pain and increase in the rebuilding of damaged cartilage tissue. Immunoglobulins and series 1, and 3, prostaglandins have also been stimulated by Cetyl Myristoleate, perhaps providing an explanation on its autoimmune and inflammatory properties.
As a fatty acid ester, CMO shows promise as a nutritional supplement administered for joint health, despite the lack of scientific knowledge of Cetyl Myristoleate’s physiologic activity.
Dosages of Cetyl Myrisoleate vary and are driven by individual need, and the severity and location of depleted cartilage. Generally, CMO is taken over a 30-day period in dosages varying from 12 to 15 grams. Dosages are administered gradually over a months time. Adequate intakes are often reported in ranges from 300 - 500 milligrams per day.
|Adults and Teenagers||Children up to age 12|
|Dosages:||12 – 15 grams per month (1-3 month period)||No specificity for this age demographic|
Cetyl Myristoleate Deficiencies
As it is not classified as an “essential” nutrient, there are no known deficiencies of CMO.
Cetyl Myristoleate Toxicities
There has been clinical toxicity studies performed regarding Cetyl Myristoleate, and these findings have deemed this nonessential nutrient non-toxic for humans in accordance to Federal regulations. Findings were a result of mammalian studies conducted in which test animals were exposed to prolonged, mega doses of CMO.  No ill effects to the animals’ external or internal physiology were reported.
1. Diehl H.W. Cetyl Myristoleate. U.S. Patent #(s) 4,049,824, 4,113,881, and #5,569,676.
2. Diehl, H. W. and May, E.L., Cetyl Myristoleate Isolated from Swiss Albino Mice: An Apparent Protective Agent Against Adjuvant Arthritis in Rats. Jour. Of Pharmaceutical Sciences, Vol. 83, No. 3, Mar, 94 pp. 296-299.
3. Private correspondence to H.W. Diehl, Rockville, Md. From Dr. Fay Wood, Univ. of Cal., Berkeley, 1969.
4. Dorland’s Medical Dictionary, 25th Ed.
5. Kraemer W.J., Ratamess NA, Anderson JM, et al. Effect of a cetylated fatty acid topical cream on functional mobility and quality of life of patients with osteoarthritis. J Rheumatol. Apr 2004;31(4):767-74.
6. Hesslink R Jr., Armstrong D III, Nagendran MV, Sreevatsan S, Barathur R. Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. Aug 2002;29(8):1708-12.
7. Shils, Olson, and Shike. Modern Nutrition in Health and Disease. Lea & Fegigen, 1994. Philadelphia, PA. p. 1480.
8. Siemandi H. The effect of cis-9-cetyl myristoleate (CMO) and adjunctive therapy on arthritis and auto-immune disease: a randomized trial. Townsend Letter for Doctors and Patients 1997;(Aug/Sept):58-63.
9. Leberco Testing, Inc., Jan. 22, 1996, private correspondence to EHP Products, Inc.